Systemic overuse of antipsychotics in U.S. nursing homes masks dementia care failures, HHS watchdog reveals structural neglect
Original framing: “STAT+: HHS watchdog slams nursing homes’ antipsychotic drug use and schizophrenia diagnoses” — STAT News
Clinical guidelines explicitly warn against antipsychotics for dementia due to risks of stroke, cognitive decline, and mortality, yet 1 in 5 U.S. nursing home residents still receive them. Studies show that non-pharmacological interventions (e.g., music therapy, reminiscence work) reduce agitation by 30-50% with no side effects, yet these are underfunded and underutilized. The diagnostic ambiguity around ‘schizophrenia’ in dementia care stems from outdated criteria (DSM-5’s ‘major neurocognitive disorder with behavioral disturbance’), which pharmaceutical companies exploit to market off-label uses. The science is clear: this is a failure of implementation, not a knowledge gap.
The HHS watchdog’s report is not an aberration but a symptom of a healthcare system that has commodified aging, where for-profit nursing homes operate as assembly-line facilities for the elderly, and antipsychotics serve as a chemical straightjacket to manage ‘difficult’ residents.
This crisis is rooted in the 1980s neoliberal shift toward privatized elder care, compounded by Medicare/Medicaid reimbursement models that reward volume over quality and a pharmaceutical industry that profits from diagnostic ambiguity. Historically, it echoes the eugenics-era institutionalization of marginalized groups, now disproportionately targeting Black and Latino elders due to structural racism in healthcare access and diagnosis. Cross-culturally, the solutions are clear: community-based models from Japan to Kerala prove that institutionalization is a policy choice, not a necessity, while Indigenous frameworks remind us that dementia care must honor the personhood of elders rather than pathologize their existence. The path forward requires dismantling the profit motive in elder care, centering marginalized voices in policy design, and investing in models that treat aging as a natural—even sacred—part of life, not a market failure to be chemically managed.